Viridian Therapeutics (VRDN) Earnings Date, Estimates & Call Transcripts $13.57 -0.10 (-0.73%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$13.56 -0.01 (-0.07%) As of 05/23/2025 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Viridian Therapeutics Earnings Summary Viridian Therapeutics posted Q1 2025 earnings on May 6, 2025, reporting an EPS of -$0.87, which beat analysts' consensus estimates of -$0.95 by $0.08. Quarterly revenue rose .0% year-over-year to $0.07 million, below analyst estimates of $0.16 million. With a trailing EPS of -$3.85, Viridian Therapeutics' earnings are expected to decrease next year, from ($4.03) to ($4.31) per share. Latest Q1 Earnings DateMay. 6EstimatedConsensus EPS (May. 6) -$0.95 Actual EPS (May. 6) -$0.87 Beat By $0.08 Actual Revenue (May. 6) $0.07MQ1 2025 Earnings ResourcesQ1 2025 Earnings Report Press Release (8-K) Quarterly Report (10-Q)SEC FilingPowered by Get Viridian Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Viridian Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataVRDN Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.VRDN Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Viridian Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20254-$1.09-$0.81-$0.97Q2 20254-$1.09-$0.82-$0.98Q3 20254-$1.08-$0.78-$0.95Q4 20254-$1.32-$0.79-$1.03 FY 2025 16 -$4.58 -$3.20 -$3.93 Q1 20262-$1.02-$0.81-$0.92Q2 20262-$1.07-$0.84-$0.96Q3 20262-$1.05-$0.82-$0.94Q4 20262-$0.95-$0.63-$0.79 Viridian Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025-$0.95-$0.87+$0.08-$0.87$0.16M$0.07M2/27/2025Q4 2024-$1.05-$0.81+$0.24-$0.81$0.05M$0.07M11/12/2024--$1.11-$1.15 -$0.04-$1.15$0.08M$0.09M8/8/2024--$0.87-$1.02 -$0.15-$1.02$0.09M$0.07M5/8/2024Q1 2024-$1.07-$0.79+$0.28-$0.79$0.09M$0.07M2/27/2024Q4 2023-$0.98-$1.35 -$0.37-$1.35$0.15M$0.07M11/13/2023Q3 2023-$1.22-$1.09+$0.13-$1.09$0.28M$0.07M8/8/2023Q2 2023-$1.26-$1.27 -$0.01-$1.27$0.25M$0.07M Viridian Therapeutics Earnings - Frequently Asked Questions When did Viridian Therapeutics announce their last quarterly earnings? Viridian Therapeutics (NASDAQ:VRDN) last announced its quarterly earning data on Tuesday, May 6, 2025. Learn more on VRDN's earnings history. Did Viridian Therapeutics beat their earnings estimates last quarter? In the previous quarter, Viridian Therapeutics (NASDAQ:VRDN) reported ($0.87) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.95) by $0.08. Learn more on analysts' earnings estimate vs. VRDN's actual earnings. How can I view Viridian Therapeutics's earnings report? Viridian Therapeutics's earnings report can be found in their filing with the SEC. View SEC filing How much revenue does Viridian Therapeutics generate each year? Viridian Therapeutics (NASDAQ:VRDN) has a recorded annual revenue of $302,000.00. How much profit does Viridian Therapeutics generate each year? Viridian Therapeutics (NASDAQ:VRDN) has a recorded net income of -$237.73 million. VRDN has generated -$3.85 earnings per share over the last four quarters. What is Viridian Therapeutics's EPS forecast for next year? Viridian Therapeutics's earnings are expected to decrease from ($4.03) per share to ($4.31) per share in the next year. More Earnings Resources from MarketBeat Related Companies Sotera Health Earnings Privia Health Group Earnings Surgery Partners Earnings Concentra Group Holdings Parent Earnings Veracyte Earnings LifeStance Health Group Earnings Ardent Health Partners Earnings Addus HomeCare Earnings GeneDx Earnings Progyny Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH StockAdvance Auto Parts Jumps on Surprise Earnings BeatAlibaba's Earnings Just Changed Everything for the StockCisco Stock Eyes New Highs in 2025 on AI, Earnings, UpgradesSymbotic Gets Big Earnings Lift: Is the Stock Investable Again?D-Wave Pushes Back on Short Seller Case With Strong EarningsAppLovin Surges on Earnings: What's Next for This Tech Standout? This page (NASDAQ:VRDN) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredAfter Monday, price goes up 600% (hurry)Right now, for a limited time… You can get up to 52 Money Monday trades for just $7! Thanks to Wall Street’...Timothy Sykes | SponsoredMemorial Day Sale! Save 85% on Weiss Crypto Investor!President Trump just made his first big crypto move … Announcing the creation of a national strategic reser...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viridian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viridian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.